medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Rapid spread of the SARS-CoV-2 δ variant in the area of Paris (France) in June 2021

Samuel Alizon[1,+], Stéphanie Haim-Boukobza[2], Vincent Foulongne[3], Laura Verdurme[2], Sabine Trombert-Paolantoni[2], Emmanuel Lecorche[2], Bénédicte Roquebert[2], Mircea T. Sofonea[1]

[1] MIVEGEC, CNRS, IRD, Université de Montpellier, Montpellier, France
[2] Laboratoire Cerba, Saint Ouen L'Aumône, France
[3] Laboratoire de Virologie, CHU de Montpellier, France * Corresponding author: samuel.alizon@cnrs.fr

Abstract

Analysing 5,061 variant-specific tests performed on SARS-CoV-2 positive samples collected in France between 31 May and 8 June 2021 reveals a rapid growth of the δ variant in the Île-de-France region. The next weeks will prove decisive but the magnitude of the estimated transmission advantage (with a 95% confidence interval between 67 and 120%) could represent a major challenge for public health authorities.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The evolution of SARS-CoV-2 variants has caused epidemic rebounds in many countries, such as the one in May 2021 in the United Kingdom (UK) caused by the δ first detected in India [1]. According to a report from Public Health England [2], this variant has a transmission advantage of approximately 66% (95% confidence interval (CI): [28,113]%) over the α variant based on within-household transmission and is slightly more prone to immune evasion [3]. As shown in 2021 with the emergence of the α variant, there is a two-month shift between the epidemic situation in France and the UK [4]. Therefore, the time is ripe to investigate the potential early spread of the δ variant to devise appropriate public health responses.

We analysed 5,061 RT-PCR variant-specific screening tests (VirSNiP E484Q/K and L452R assay, from Tib Mol Biol) performed on samples collected between 31 May and 8 June 2021 that were tested positive for SARS-CoV-2. The VirSNiP test screens for the presence of the E484K, the E484Q, and the L425R mutations (Supplementary Methods). A 484K-/484Q+/452R+ profile is in favour of B.1.617.1 or B.1.617.3 lineages, whereas a 484K-/484Q-/452R+ profile is in favour of a B.1.617.2 lineage. These tests originated from different French regions, with a dominance of the Île-de-France and the Paris area (2,443/5,061 tests, i.e. 48%). Most of the tests originated from non-hospitalised individuals (4,775/5,061 tests, i.e. 94%) (Supplementary Table S1).

Variant-screening test results

Using a multinomial regression model as in [5], we found that samples bearing the L452R mutation and neither the E484K nor the E484Q mutation, i.e. consistent with the variant δ genotype, tended to increase in the Île-de-France region compared to samples without any of the three mutations, i.e. consistent with the variant α genotype (Table 1).

Furthermore, samples collected outside hospital settings are less likely to orginate from β, γ, or η variants than from α variant (set as reference). Finally, in the Hauts-de-France region, we found an increasing trend of β, γ, or η variants compared to the α variant (set as reference). In most regions, we found a temporal increase of 'other' variants compared to the α variant (set as reference). This is more difficult to analyse since a part of these latest tests are uninterpretable (16,4% of the total). Finally, we find a temporal increase of the δ variant compared to the α variant in the regions that were less densely sampled.

Table 1: Factors associated with the detection of potential SARS-CoV-2 variants, as assessed by relative risk ratios using a multinomial log-linear model, France, 31 May-8 June 2021 ($n = 5,061$). See [5] for details about the methods used.

	$\beta/\gamma/\eta$-like	**delta-like**	**other**
age	NS [0.97,1.10]	NS [0.94,1.30]	NS [0.98,1.10]
location (non-hospital)	0.54 [0.40,0.74]	NS [0.61,3.80]	NS [0.74,1.30]
date:Normandie	NS [0.89,1.30]	NS [0.65,1.50]	NS [0.95,1.30]
date:Hauts-de-France	1.37 [1.10,1.80]	NS [0.850,2.30]	1.30 [1.10,1.60]
date:Ile-de-France	NS [0.88,1.10]	1.49 [1.20,1.90]	1.10 [1.00,1.20]
date:other	NS [0.87,1.30]	1.68 [1.20,2.30]	1.28 [1.10,1.50]

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 1: **Estimated transmission advntage of the δ variant with respect to all the other lineages in Ile-de-France, 31 May-8 June 2021.** The triangles indicate the GLM-fitted values and the line the output of the logistic growth model estimation. The shaded area represents the 95 %CI. The title indicates the estimated transmission advantage of the δ variant over the other lineages.

Transmission advantages

To further quantify the temporal trends, we performed a statistical analysis using a logistic growth model following previous studies [6, 4]. We found that in Île-de-France the transmission advantage of the positive samples bearing the L452R mutation and neither the E484K nor the E484Q mutations (i.e. potential δ variants) compared to all the other samples is 92% (95% CI: [67,120]%) (Figure 1A).

In Hauts-de-France, we estimated the transmission advantage of the positive samples bearing the E484K mutation and not the E484Q mutations (i.e. potential β, γ, or η variants) compared to all other samples was 56% (95% CI: [42,71.9]%).

Discussion

The analysis of the first tests designed to screen SARS-CoV-2 mutations bore by the δ variant collected between 31 May and 8 June 2021 indicate that this variant might already be spreading rapidly in the area of Paris, and potentially in other regions of France. According to our estimates, by mid-June 2021 its frequency in the Île-de-France region could already be above 10%.

There are several potential biases to this analysis, which we attempted to correct. First, since our dataset gathers results from local laboratories, there can be delays in data collection. To address this, we

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

collected the data available on 16 June 2021, which included tests results as recent as June 14, and only analysed the data up to June 8. Note that analysing all the samples yielded qualitatively similar results except for an increase in the δ variant in the Hauts-de-France region according to the multinomial model.

Another potential issue has to do with the specificity of the test used. However, the frequency of δ variant we estimate, which was in the order of 4% of the positive tests on June 8, is consistent with the outcome of national sequencing studies (0.2% on 11 May 2021 [7]) although with a short doubling time (approximately 8 days). Furthermore, our estimate is conservative since we treat all the samples that are uninterpretable or where the signal is weak as non-δ variant samples.

Regarding the sampling scheme, the French authorities have announced a strict monitoring of the spread of the δ variant, which means that contact tracing could be more intense. This could, therefore, artificially enrich the data in δ variant positive test. We do not have access to the details regarding the context of the test. However, we do know that some tests were performed in a hospital setting, mainly for hospitalised patients. If there was a strong bias generated by better contact tracing, we would expect samples from hospitals to differ because it would likely be less important here (aside from nosocomial transmission, the contacts of a hospitalised person are likely not to be hospitalised). We find no effect of the hospitalisation status in the multinomial model and running the analyses on the hospitalised samples only yielded a similar trend (although with a large 95% CI: 81% [19,166]%).

Finally, from a methodlogical point of view, our estimation of the transmission advantage assumes that the transmission fitnesses of the different lineages to not vary over time. This is unlikely to be the case with the ongoing vaccination campaign and the variations in natural immunity. However, the short time period considered for this analysis justifies this assumption.

The estimated transmission advantage in the Île-de-France appears to be higher than that estimated in the UK [2]. One possibility could be due to specific contact-tracing. Another could be due to the vaccination coverage in France compared to the UK [8]. Indeed, early evidence suggests that the δ variant could be evading immunity more than the α variant [3].

These results have major public health implications because, given the current estimates for the French epidemic reproduction number ($R_t \approx 0.8$), they imply that variant δ could be spreading rapidly (with $R_t^\delta \geq 1.2$). In absence of specific interventions and based on the current vaccine rollout, a model tailored to the French epidemic [9] suggests that this could cause another epidemic wave starting in August 2021. The magnitude and exact timing of this wave would depend on the exact transmission advantage of the variant.

Acknowledgements

We thank Gilles Roullin, Eric Hedbaut and Virginie Dubois from CERBA for their technical assistance, and the ETE team from CNRS, IRD, and University of Montpellier for discussion.

Conflict of interests

None declared.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Ethical statement

This study has been approved by the Institutional Review Board of the CHU of Montpellier and is registered at ClinicalTrials.gov with identifier NCT04738331.

References

[1] World Health Organisation. Tracking SARS-CoV-2 variants; 2021. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

[2] Public Health England. SARS-CoV-2 variants of concern and variants under investigation - Technical briefing 15; 2021. 15. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993879/Variants_of_Concern_VOC_Technical_Briefing_15.pdf.

[3] Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021;p. 2021.05.22.21257658.

[4] Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, et al. Detection of Rapid SARS-CoV-2 Variant Spread, France, January 26–February 16, 2021. Emerg Infect Dis. 2021;27(5):1496–1499.

[5] Roquebert B, Trombert-Paolantoni S, Haim-Boukobza S, Lecorche E, Verdurme L, Foulongne V, et al. The SARS-CoV-2 B.1.351 lineage (VOC β) is outgrowing the B.1.1.7 lineage (VOC α) in some French regions in April 2021. Eurosurveillance. 2021;26(23):2100447.

[6] Chevin LM. On measuring selection in experimental evolution. Biology Letters. 2011;7(2):210–213.

[7] Santé Publique France. Quelle est l'évolution moléculaire des virus SARS-CoV-2 circulant sur le territoire ? Résultats de l'enquête Flash#9;. Accessed on 16 June 2021. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/enquetes-etudes/quelle-est-l-evolution-moleculaire-des-virus-sars-cov-2-circulant-sur-le-territ

[8] Max Roser EOO Hannah Ritchie, Hasell J. Coronavirus pandemic (COVID-19); 2020. Available from: https://ourworldindata.org/coronavirus.

[9] Sofonea MT, Reyné B, Elie B, Djidjou-Demasse R, Selinger C, Michalakis Y, et al. Memory is key in capturing COVID-19 epidemiological dynamics. Epidemics. 2021;p. 100459.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary materials

S1 Methods

We analyse the qualitative outcome of the SARS-CoV-2 VirSNiP E484Q/K and L452R assay from Tib Mol Biol performed on samples that tested positive for SARS-CoV-2 in partner laboratories, mainly using partly the PerkinElmer SARS-CoV-2 Real-time RT-PCR Assay (Perkin Elmer).

The VirSNiP test targets three mutations specifically (E484K, E484Q, and L462R). Based on the genomics of the different lineages and their prevalence in France, the test results are interpreted as follows:

- E484K-/E484Q-/L462R-: potential infection by the α variant
- E484K-/E484Q-/L462R+: potential infection by the δ variant
- E484K+/E484Q-/L462R-: potential infection by the β, γ, or η variant

All the other combinations were rare and grouped in the "other" category (see below for the details).

The data was extracted on June 16, 2021 and the most recent test results were from June 14, 2021. However, to correct for potential delays in the recording of the results from local partners, we did not include any tests performed after June 8, 2021. We also only included from individuals from 5 to 80 years old, and included at most one sample per individual.

S2 Data

The characteristics of the data are shown in Table S1.

Among the 'other' test results, the majority corresponded to uninterpretable test results (751/1394, i.e. 54%) and a large fraction to tests without the L452R mutant and an ambiguity for the E484 mutation (524/1394, i.e. 38%), which could be indicative of an infected by a β, γ, or η variant with a low virus load. Note that this assumption is conservative to avoid overestimating the spread of the δ variant. In fact, some of the tests in the 'other' category (74/1394, i.e. 5%) find a clear signal for the L452R mutation with an ambiguity regarding the E484 mutation and could, therefore, be associated with this variant.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.16.21259052; this version posted June 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table S1: Characteristics of the samples analysed via the VirSNiP assay, France, 31 May-8 June 2021 ($n = 5,061$).

Characteristics		**Value**
Age	*median [min,max]*	34 [5,80]
Sample origin	general population	4775 (94.3%)
	hospital	286 (5.7%)
Sampling date	*median [min,max]*	June 3 [May 31, June 8]
Region	Ile-de-France	2443 (48.7%)
	Normandie	946 (18.9%)
	Hauts-de-France	611 (12.2%)
	other	1014 (20.2%)
Test result	alpha-like	2833 (56.0%)
	beta/gamma/B.1.525-like	695 (13.7%)
	delta-like	139 (2.7%)
	other	1394 (27.5%)